Clinical trial · Observational
CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
Clinical Outcome of CT-guided Radioactive Iodine-125 Seeds Implantation for Inoperable Early Stage Non-small Cell Lung Cancer
NCT03916367CI-TRIAL-00038724completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Stage Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-guided Radioactive I-125 Seeds Implantation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Early Stage Lung Cancer
- description
- The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
- interventionNames
- Radiation: CT-guided Radioactive I-125 Seeds Implantation
Primary outcomes (2)
- measure
- Local control time
- timeFrame
- Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
- description
- The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation.
- measure
- Overall survival time
- timeFrame
- Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * histological proven non-small cell lung cancer * UICC (Union for International Cancer Control) stage was T1-3N0M0 (stage Ia-IIb) * inoperable and CT-guided radioactive iodine-125 seeds brachytherapy was used as the initial treatment without external beam radiotherapy Exclusion Criteria: * actual dose of covers 90% target volume (D90) less than 100 Gy in postoperative validation * case information and/or follow-up information was unavailable
References
Publications (0)
Data not yet available
No reference posted for this study.